1
Paris May 03 2018 Leader in Allergenic Peptide Immunotherapy
Thierry LegonCEO, ASIT biotech
2
About ASIT biotech
Mission
To improve acceptance and compliance of allergy immunotherapy by developing short course treatments based on innovative allergenic peptides
Main achievements
• Clinical efficacy of lead product in Grass Pollen Rhinitis confirmed in Phase 3 clinical study
• Validated technology platform to design, characterize, screen and produce novel product candidates
• Ongoing design and screening of product candidates in House Dust Mite Rhinitis and food allergy (peanuts, cow’s milk and egg white)
3
About ASIT biotech
• ASIT biotech has dual market listing in Brussels (Belgium) and Paris (France) since May 2016
• Raised €73 million since inception (€23.4 million by IPO (2016) and €13.9 million by a private placement (2018))
• 26 active and motivated collaborators
• Partnership with public and private internationally renowned institutions
4
Ever increasing number of allergic patients
5
Over 1 billion patients suffer today from Allergy and over 4 billion in 2050
• Steadily increasing prevalence of allergic diseases
• More complex allergies with high morbidity leading to a heavy burden for health care system
• 30 to 40% of the world population would be affected by one or more allergic conditions
World Allergy Week April 2011EAACI
✓ Over 400 million patients suffer from Allergic Rhinitis✓ Over 200 million patients suffer from Food allergies✓ Over 300 million patients suffer from Asthma
6
Allergic Rhinitis:up to 400 million people worldwide
Bauchau V & Durham SR Eur Respir J 2004; 24: 758-764 Katelaris, C.H. et al., 2012. Clinical and experimental allergy 42(2), pp.186–207C.F., M. & Tong Janice S.C. Lin, 2015. European Academy of Allergy and Clinical Immunology, pp. 62–63.
USA Europe China Japan
Population (M) 320 320 1379 127
Population withRhinitis (M)
43 73 TBD 38
Population withsevere Rhinitis (M)
24 25 TBD 9
USA12-30%
EUROPE23-30%
CHINA1,6-43%
LATINAMERICA5,5-45,1%
AFRICA7,2-54,1%
AUSRALIA12-41,3%
JAPAN9,1-37,5%
MIDDLE EAST7,4-45,2%
7
• 15 million of American, 17 million of Europeans suffer from food allergy1
• Increasing prevalence in both developed and developing countries2
• Peanut, cow’s milk and egg white concern >74% children3
• Total annual food allergy management cost estimate/child in the US: $ 4,184
1. Commins et al. 2016 and World Allergy Organization2. Prescott et al. 20133. Scott et al. 20114. Gupta et al 2013
Food Allergy:more than 200 millions people worldwide
8…if not threathening life…
Reduced work productivity
Eye symptoms
Nasalsymptoms
Sleep deprivation
Reducedschool performance
AngiodemaAsthma
Allergy leads to symptomsimpairing quality of life
9
Allergy: inappropriate immune response against harmless substance
Th2
cell
BasophilMast cell
B cell
Eosinophils
recruitment and activation
Allergens
Antigen
Presenting
cell
Degranulation leading to
histamine release
IgE
synthesis
BasophilMast cell
1
54
3
2
1. First contact between allergen and mucosa
2. Allergen specific IgE antibody production
‒ Uptake & processing by APC
‒ T- cell activation‒ allergen specific IgE
antibody production3. Loading of allergen specific IgE on
mast cells4. Bridging of the IgE by allergens5. Allergic reaction
10
Therapeutic options: Symptomatic vs Curative
11
Symptomatic drugs for allergic rhinitis
Allergic rhinitis & asthma• >95% of the market• daily intake during allergen
exposure (seasonal/perennial)
• no long-term effect• poor effectiveness in case of
low compliance• $20 billion/year for
respiratory allergies
Food allergy• no registered drugs available• food avoidance• epinephrine injection
AntihistaminesZyrtecXyzal
AllegraClaritin
IgE-specific blockers (mAb)
Omalizumab (Novartis/Genentech)
Interleukin specific blockers (mAb)
Mepolizumab (GSK)Reslizumab (Teva)Benralizumab (AZ)
Dupilumab(Regeneron/Sanofi)
Nonspecific immunosuppressorsIntranasal steroids
Inhaled steriodsLeukotriene modifiers
B cell
Th2
cell
IgE
synthesis
BasophilMast cell Eosinophils
recruitment
and
activation
Allergen
Antigen
Presenting
cell
Degranulation
leading to
histamines
release
BasophilMast cell
12
Sub-cutaneous Sublingual
Curative treatment: Allergy Immunotherapy
13
1. Regulatory T and B cells 2. Prevention of the seasonal
increase of IgE3. Induction of IgG4-associated
blocking antibodies leading to clinical benefit during the pollen season.
4. Suppression of grass pollen-induced basophil activation responsible for immediate allergic response
Th2
cell
IgE synthesis
BasophilMast cell Eosinophils
recruitment and
activation
Allergen
Antigen
Presenting
cellWhole Allergens
BasophilMast cell
Treg
cell Breg
cell
B cell IgG4 & IgA
synthesis
-
-
-
+
+ IL-1
0IL
-35
1
2
3
2
4
Degranulation leading to
histamine release
Allergy immunotherapy induces natural regulation of the immune system and provides better symptoms reduction
14
Allergy immunotherapy market less than €1billion today
SCITSubcutaneous
immunotherapy
SLITSublingual
immunotherapy
Year 1 Year 2 Year 3
SCIT 40-60Doctor visits
Daily administration
180 to 360 days/year
COMPLIANCE
< 25%
< 12.5%
3 year long cumbersome treatment due to the use of whole allergen extracts
15
Whole allergen extract limitations
Allergen injections
IgG and IgG4
IgE
Lymphocyte responses
6 months 2 years
Allergen Injections
Time
Symptoms
Safety concerns: induction of histamine and proinflammatory substances
Efficacy concerns: delay in reaching the optimal balance between IgG4 and IgE
16
ASIT™ Innovative technology
17
ASIT+™ allergenic peptides allow short-course treatment improving patient adherence and compliance
4 doctor visits in 3 weeks before each pollen season
4 visits
ASIT biotech’sOffer
18
ASIT+TM Immunotherapy
✓ Short course SCIT
✓ Real-life clinical efficacy during grass pollen season confirmed
✓ Fast onset of optimal immunoregulation with blocking antibodies induction
✓ Applicable to all allergies
✓ No need of adjuvant
✓ Probable high patient adherence and compliance
Optimally-sized
natural allergenic peptides
(1 – 10 kDa)
Current Immunotherapy
Whole Allergens
Advantages
✓ Clinically effective
✓ Safety: SLIT > SCIT
✓ Include all the necessary immunological information
✓ IgG4 and blocking antibodies
✓ Applicable to all allergies
Disadvantages
Increased AEs
3 year treatment
Poor patient compliance
Need of adjuvants
ASIT+TM unique safe and efficient active ingredients
ASIT+TM Technology Platform
19
ASIT+TM technology platform to design, characterize, screen and produce novel product candidates
Large proteins do not enter into the gel particles=> shorter pathway through the column.
ASIT+TM allergenic peptides enter intothe gel particles=> longer pathway through the column.
Extraction of allergens from natural source
Enzymatic hydrolysis
Selection of allergenic peptides according to size
(1-10kDa)
20
ASIT™ Clinical Development
21
ASIT biotech pipeline: achieved milestones
Pre-clinical Phase I Phase II Phase III
Grass pollen
Q1 2017 - Positive phase III
gp-ASIT+™
hdm-ASIT+™
Q2 2017 - Positive Phase I/II
House dust mite
Preclinical development program
food-ASIT+™
FoodPeanut - Egg white - Cow’s milk
22
gp-ASIT+™ Positive Phase III clinical study (BTT009)
• symptom and drug intake reduction statistically significant -15.5% during the peak and -17.9% over the pollen season (p<0.05).
• all the results pointed to symptom improvement
• robust immunological results supporting the clinical efficacy and paving the road of the preclinical development of other ASIT+TM products for other indications
• next Phase III in 2019
‒ 2:1 (active : placebo)‒ 93% retention rate: 512
patients attended the last visit
‒ Clinical efficacy during pollen season based on reduction in the combined symptom-medication score (CSMS)
‒ Double-blind‒ Placebo controlled‒ 67 centers in Europe
TRIAL # PATIENTS PRIMARY OBJECTIVE DESIGN
Phase III
23
ASIT™ mechanistic aspects
Prof. Mohamed Shamji
Short Course treatment of Subcutaneous Peptide Hydrolysate from Lolium Perenne suppresses Basophil Responses and induces IgG-associated
Blocking Antibodies: A RDPCT
Mohamed Shamji, PhD. CS. FAAAAI
Head, Immunomodulation and Tolerance Group
Director, Immune Tolerance Network Distributed Centre of Excellence for Allergy & Asthma, UK
Chair, Scientific Program Committee, European Academy, Allergy and Clinical Immunology
Associate Professor in Immunology and Allergy,
Allergy & Clinical Immunology, Imperial College London, UK
Media & Analyst Conference, Paris, France
Thursday, 3rd May, 201824
25
ILC2Cell
Th2Cell
B Cel
l
Eosinophil Plasma
Cell
Th0
Mast CellAllergen-
specific IgE
Natural exposure(Low-dose allergen)
Dendritic cells(nasal mucosa)
Basophil
Pathophysiology of Allergic Rhinitis and Mechanisms of AIT
TfhCell
CRTH2+ T cells
CXCR5+ T cells
IL-5
IL-9
IL-4IL-21IL-13
Shamji et al., JACI
26
Year 1 Year 2 Year 3
SCITSubcutaneous
immunotherapy
SLIT
Sublingual immunotherapy
Daily administration
180 to 365 days/year
SCIT 40-60 doctor visits
4-5 doctor visits 3 weeks prior each
pollen season
Novel
Approach AIT
Compliance
<25%
<12.5%
Kiel et al., J Allergy Clin Immunol 2013;132:353-60
27
Pollen proteins - batch 1
Pollen proteins - batch 2
Pollen peptides - batch 1
Pollen peptides - batch 2
Basophil activation
*p ≤ 0.05
**p ≤ 0.05
***p ≤ 0.05
Concentration [µg/ml]
1e-4 0,001 0,01 0,1 1 10 100 1000
0
20
40
60
80
Graph#8
4-P Fit: y = (A - D)/( 1 + (x/C)^B ) + D: A B C D R^2
Plot#2 (PROT 08J20 (1/3): Concentration vs %IN... -0.72 0.973 0.0861 95.7 0.999
Plot#4 (PROT 00597 (1/3): Concentration vs %IN... 4.86 0.835 0.0905 97.9 1
Plot#6 (PEP 00597 (1/3): Concentration vs %INHIB) -8.18 0.269 136 143 0.999
Plot#10 (PEP 08K05 (1/3): Concentration vs %INH... -12.8 0.227 497 170 0.998__________
Weighting: Fixed
IgE
bin
din
g (
%)
Concentration [µg/ml] Concentration [ng/mL]
CD
63
+ b
aso
ph
ils[%
]
Reproducibility
Characterisation of Peptide Hydrolysate from Lolium Perenne
(gpASIT+TM) and its ability to bind to IgE compared to Grass Pollen
extract
Shamji et al., JACI 2017
28
Pollen proteins - batch 1
Pollen proteins - batch 2
Pollen peptides - batch 1
Pollen peptides - batch 2
Basophil activation
*p ≤ 0.05
**p ≤ 0.05
***p ≤ 0.05
Concentration [µg/ml]
1e-4 0,001 0,01 0,1 1 10 100 1000
0
20
40
60
80
Graph#8
4-P Fit: y = (A - D)/( 1 + (x/C)^B ) + D: A B C D R^2
Plot#2 (PROT 08J20 (1/3): Concentration vs %IN... -0.72 0.973 0.0861 95.7 0.999
Plot#4 (PROT 00597 (1/3): Concentration vs %IN... 4.86 0.835 0.0905 97.9 1
Plot#6 (PEP 00597 (1/3): Concentration vs %INHIB) -8.18 0.269 136 143 0.999
Plot#10 (PEP 08K05 (1/3): Concentration vs %INH... -12.8 0.227 497 170 0.998__________
Weighting: Fixed
IgE
bin
din
g (
%)
Concentration [µg/ml] Concentration [ng/mL]
CD
63
+ b
aso
ph
ils[%
]
Characterisation of Peptide Hydrolysate from Lolium Perenne
(gpASIT+TM) and its ability to bind to IgE compared to Grass Pollen
extractReproducibility
Shamji et al., JACI 2017
29
Pollen proteins - batch 1
Pollen proteins - batch 2
Pollen peptides - batch 1
Pollen peptides - batch 2
Basophil activation
*p ≤ 0.05
**p ≤ 0.05
***p ≤ 0.05
Concentration [µg/ml]
1e-4 0,001 0,01 0,1 1 10 100 1000
0
20
40
60
80
Graph#8
4-P Fit: y = (A - D)/( 1 + (x/C)^B ) + D: A B C D R^2
Plot#2 (PROT 08J20 (1/3): Concentration vs %IN... -0.72 0.973 0.0861 95.7 0.999
Plot#4 (PROT 00597 (1/3): Concentration vs %IN... 4.86 0.835 0.0905 97.9 1
Plot#6 (PEP 00597 (1/3): Concentration vs %INHIB) -8.18 0.269 136 143 0.999
Plot#10 (PEP 08K05 (1/3): Concentration vs %INH... -12.8 0.227 497 170 0.998__________
Weighting: Fixed
IgE
bin
din
g (
%)
Concentration [µg/ml] Concentration [ng/mL]
CD
63
+ b
aso
ph
ils[%
]
Shamji et al., JACI 2017
Reproducibility
Characterisation of Peptide Hydrolysate from Lolium Perenne
(gpASIT+TM) and its ability to bind to IgE compared to Grass Pollen
extract
30
Hypotheses
- 3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne(LPP, gpASIT+TM) is associated with reduction in CSMS and RTSS during thepeak and throughout the entire pollen season.
- gpASIT+TM immunotherapy but not placebo blunts the seasonal increases ofsIgE
- gpASIT+TM immunotherapy but not placebo treatment suppresses grass pollen-induced basophil hyperesponsivess and basophil reactivity.
- A short-course of gpASIT+TM immunotherapy induces IgG4-associatedblocking antibodies that conferred clinical benefit during the pollen season andsupresses pathogenic T cell responses.
31
Hypotheses
- 3-week treatment with subcutaneous peptide hydrolysates from Loliumperenne (LPP, gpASIT+TM) is associated with reduction in CSMS andRTSS during the peak and throughout the entire pollen season.
- gpASIT+TM immunotherapy but not placebo blunts the seasonal increases ofsIgE
- gpASIT+TM immunotherapy but not placebo treatment suppresses grass pollen-induced basophil hyperesponsivess and basophil reactivity.
- A short-course of gpASIT+TM immunotherapy induces IgG4-associated blockingantibodies that conferred clinical benefit during the pollen season andsupresses pathogenic T cell responses.
Study design – RDBCT
CSMS
Mechanistic analyses
Immune mechanisms analyses on participant from a single site - (Ghent, Belgium).
32
33
CSMS during the peak pollen and the entire pollen season following LPP and Placebo
CSMS – Peak seasonCSMS – Peak season CSMS – Entire season
Mösges and Shamji, Allergy 2018
34
3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne (LPP, gpASIT+TM) supresses CSMS and
RTSS
CSMS RTSS
CSMS reduction in BelgiumPeak period : -35.1%; P=0.03.Entire pollen season : -53,7%; P=0.03
RTSS reduction in Belgium
Peak period: -27.4%, P=0.04
Entire pollen season: -56.9%, P=0.01
Shamji MH et al, EAACI 2017
35
Hypotheses
- 3-week treatment with subcutaneous peptide hydrolysates from Loliumperenne (LPP, gpASIT+TM) is associated with reduction in CSMS andRTSS during the peak and throughout the entire pollen season.
- gpASIT+TM immunotherapy but not placebo blunts the seasonal increases ofsIgE
- gpASIT+TM immunotherapy but not placebo treatment suppresses grass pollen-induced basophil hyperesponsivess and basophil reactivity.
- A short-course of gpASIT+TM immunotherapy induces IgG4-associated blockingantibodies that conferred clinical benefit during the pollen season andsupresses pathogenic T cell responses.
36
Hypotheses
- 3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne(LPP, gpASIT+TM) is associated with reduction in CSMS and RTSS during thepeak and throughout the entire pollen season.
- gpASIT+TM immunotherapy but not placebo blunts the seasonal increasesof sIgE
- gpASIT+TM immunotherapy but not placebo treatment suppresses grass pollen-induced basophil hyperesponsivess and basophil reactivity.
- A short-course of gpASIT+TM immunotherapy induces IgG4-associated blockingantibodies that conferred clinical benefit during the pollen season andsupresses pathogenic T cell responses.
37
V8-V6
V2 = Before treatment
V6 = After treatment
V8 = After the grass pollen season
Effect of LPP (gpASIT+TM) immunotherapy on sIgE levels
Shamji MH et al, EAACI 2017
38
Effect of LPP (gpASIT+TM) immunotherapy on sIgE levels
V8-V6
V2 = Before treatment
V6 = After treatment
V8 = After the grass pollen season
Shamji MH et al, EAACI 2017
39
Hypotheses
- 3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne(LPP, gpASIT+TM) is associated with reduction in CSMS and RTSS during thepeak and throughout the entire pollen season.
- gpASIT+TM immunotherapy but not placebo blunts the seasonal increasesof sIgE
- gpASIT+TM immunotherapy but not placebo treatment suppresses grass pollen-induced basophil hyperesponsivess and basophil reactivity.
- A short-course of gpASIT+TM immunotherapy induces IgG4-associated blockingantibodies that conferred clinical benefit during the pollen season andsupresses pathogenic T cell responses.
40
Hypotheses
- 3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne(LPP, gpASIT+TM) is associated with reduction in CSMS and RTSS during thepeak and throughout the entire pollen season.
- gpASIT+TM immunotherapy but not placebo blunts the seasonal increases ofsIgE
- gpASIT+TM immunotherapy but not placebo treatment suppresses grasspollen-induced basophil hyperesponsivess and basophil reactivity.
- A short-course of gpASIT+TM immunotherapy induces IgG4-associated blockingantibodies that conferred clinical benefit during the pollen season andsupresses pathogenic T cell responses.
41
Effect of gpASIT+TM and Placebo on CD203chighCRTH2+
Basophils
****
*
******
*
Shamji MH et al, EAACI 2017
42
Hypotheses
- 3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne(LPP, gpASIT+TM) is associated with reduction in CSMS and RTSS during thepeak and throughout the entire pollen season.
- gpASIT+TM immunotherapy but not placebo blunts the seasonal increases ofsIgE
- gpASIT+TM immunotherapy but not placebo treatment suppresses grasspollen-induced basophil hyperesponsivess and basophil reactivity.
- A short-course of gpASIT+TM immunotherapy induces IgG4-associated blockingantibodies that conferred clinical benefit during the pollen season andsupresses pathogenic T cell responses.
43
Hypotheses
- 3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne(LPP, gpASIT+TM) is associated with reduction in CSMS and RTSS during thepeak and throughout the entire pollen season.
- gpASIT+TM immunotherapy but not placebo blunts the seasonal increases ofsIgE
- gpASIT+TM immunotherapy but not placebo treatment suppresses grass pollen-induced basophil hyperesponsivess and basophil reactivity.
- A short-course of gpASIT+TM immunotherapy induces IgG4-associatedblocking antibodies that conferred clinical benefit during the pollenseason and supresses pathogenic T cell responses.
44
Induction of Blocking antibodies following gpASIT+TM and Placebo
Lolium PerennePhleum Pratense
* *
Shamji MH et al, EAACI 2017
45
Induction of blocking antibodies is associated with the induction of regulatory B cells in gpASIT+TM treated group.
*
* * *
Shamji MH et al, EAACI 2018
46
gpASIT+TM is associated with reduction of IL-4+Tfh cells induction of IFN-g+ Tfh cells and FoxP3+ Tfh cells
* ** *
* *
Sharif and Shamji MH et al, AAAAI 2017
47
Summary/Conclusions
- 3-week treatment with subcutaneous peptide hydrolysates from Lolium perenne(LPP, gpASIT+TM) is associated with reduction in CSMS and RTSS during thepeak and throughout the entire pollen season.
- gpASIT+TM immunotherapy but not placebo blunts the seasonal increases ofsIgE
- gpASIT+TM immunotherapy but not placebo treatment suppresses grass pollen-induced basophil hyperesponsivess and basophil reactivity.
- A short-course of gpASIT+TM immunotherapy induces IgG4-associatedblocking antibodies that conferred clinical benefit during the pollen season andsupresses pathogenic T cell responses.
48
ILC2Cell
Th0
IL-27
Immunotherapy(High-dose allergen)
Dendritic cells (under skin or oral
mucosa)
Th2Cell
B Cell
Eosinophil Plasma Cell
Th0
Mast CellAllergen-
specific IgE
Natural exposure(Low-dose allergen)
Dendritic cells(nasal mucosa)
Basophil
Proposed Mechanisms of gpASIT+TM
TfhCell
Th1
Cell
IFN-γ
Bregscell
IL-10/IL-35 Allergen-specificIgG4 & IgA
IgG4 and IgAcompetes with IgE for allergen
binding
TGF-β
Plasma Cell
IL-10
iTreg
IL-10+
nTregFoxp3+
iTregTGF-β+
Tfrcell
CTL-4
CRTH2+ T cells
CXCR5+ T cells
IL-5
IL-9
IL-4IL-21IL-13
Shamji MH et al, JACI 2017
49
Acknowledgments
Angeliki Karamani, BSc
Rebecca Parkin, BSc
Aliya Datoo
Iesha Singh, MSc
Lubna Kousar, PhD
Hanisah Sharif, MSc
Abigail Rob, Bsc
Stephen Durham, MD.FRCP
Oleksandra (Sasha) Fedina,
Ludo Haazen, MD
Sabine Pirotton, PhD
Nathalie Wathelet, PhD
Marie-Alix Bonny
Nicolas Bovy, PhD
Julie Halkein, PhD
Valeria Karusinova
Gael Placier, PhD
Jean Duchateau, MD, PhD
Thierry Legon, MBA
Ralph Mösges, MD, PhD,
Elena M. Kasche, MD,
Esther Raskopf, PhD,
Jaswinder Singh, MSc,
Lea Sohlich
Anatoli Astvatsatourov, PhDa, Kija
Shah-Hosseini
Claus Bachert, MD, PhD
Philip Gaevert, MD, PhD
Lara Derycke, MD
Gabrielle Holtapples, MSc
Jean Ceupens, MD
Peter Helings, MD,
50
hdm-ASIT+™ for house dust mite rhinitisfirst in man clinical study: safety of ASIT+TM confirmed
• 27 patients treated with hdm-ASIT+™ - 9 placebo.
• safety and tolerability of hdm-ASIT+™ confirmed
• slight positive immunological and clinical impact in a limited number of treated patients
• new product prototypes in development to be tested by Prof. M. Shamji at ICL to optimize the product candidates immunogenicity
‒ 36 patients randomized‒ Assessment of the maximum tolerated
dose ‒ Safety and clinical tolerability‒ Immunogenicity ‒ Impact on reactivity to a challenge test
‒ Q2 2017
TRIAL # PATIENTS AIM COMPLETED
Phase I/IIa
51
‒ Selection of product candidatepeanut, cow’s milk & egg white
‒ ex vivo safety and tolerability‒ ex vivo immunogenicity
‒ Q2 2018
PRE-CLINICAL DEVELOPMENT AIM COMPLETED
Product prototype ex
vivo screening
food-ASIT+™ for food allergyproduct prototypes screening on-going
• non-dilutive funding from the Walloon Region to co-finance 55% 1
• collaboration with Prof. M. Shamji (ICL), and Dr. S. Till (King’s)
• first-in-man Phase I/II trial in peanut allergy expected to be conducted from H1 2018 to end-2019
1 a recoverable cash advance granted in January 2017
52
ASIT biotech pipeline: next milestones
Pre-clinical Phase I Phase II Phase III
Grass pollen
gp-ASIT+™ FDA meeting - H2 2018Second Phase III Q4 2018 - Q4 2019
hdm-ASIT+™House dust mite
Selection of a new ASIT+TM active ingredient - Q2 2018Second Phase I/II clinical trial with improved prototype - Q1 2019
FoodPeanut - Egg white - Cow’s milk
food-ASIT+™ Selection of ASIT+TM active ingredient for peanut - Q2 2018First Phase I/II clinical trial in food - H2 2018
53
Summary
54
Short course immunotherapy with ASIT biotech’s allergenic peptides addresses the unmet needs of all stakeholders
Patient
• Efficient: Reduction of symptoms and rescue medication in the real life & Improved quality of life
• 4 doctor visits
• Time & Money saving
Healthcare systems
• Documented safety and efficacy
• Improved acceptance
• Improved compliance
• Improved real-life efficacy
• Reduced direct & indirect costs
Allergists
• New therapeutic option
• More patient accepting AIT
• Patients more compliant
• Fast onset of action
• Better patient follow-up
• Higher patient satisfaction
4 visits/year
55
Paris May 03 2018 Leader in Allergenic Peptide Immunotherapy
Merci pour votre attention !
56
Disclaimer
• THIS DOCUMENT AND ANY MATERIALS DISTRIBUTED IN CONNECTION WITH THIS DOCUMENT ARE NOT DIRECTED TO, OR INTENDED FOR DISTRIBUTION TO OR USE BY,ANY PERSON OR ENTITY THAT IS A CITIZEN OR RESIDENT OR LOCATED IN ANY LOCALITY, STATE, COUNTRY OR OTHER JURISDICTION WHERE SUCH DISTRIBUTION,PUBLICATION, AVAILABILITY OR USE WOULD BE CONTRARY TO LAW OR REGULATION OR WHICH WOULD REQUIRE ANY REGISTRATION OR LICENSING WITHIN SUCHJURISDICTION. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAW AND PERSONS INTO WHOSE POSSESSION THISDOCUMENT COMES SHOULD INFORM THEMSELVES ABOUT, AND OBSERVE ANY SUCH RESTRICTIONS.
• This presentation has been prepared by the management of ASIT biotech SA (the Company). It does not constitute or form part of, and should not be construed as,an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company nor should it or any part of it form the basis of, or berelied on in connection with, any contract to purchase or subscribe for any securities of the Company, nor shall it or any part of it form the basis of or be relied on inconnection with any contract or commitment whatsoever.
• This presentation is not a prospectus and recipients should not purchase, subscribe for or otherwise acquire any securities of the Company except on the basis of information in a prospectus or in the annual report approved by the FSMA. Copies of the prospectus and annual report issued are available on the website of the Company or at the Company’s registered office.
• The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision andamendment and such information may change materially. No person is under any obligation to update or keep current the information contained in this presentationand any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness,accuracy, reasonableness or completeness of the information contained herein. Neither the Company nor any other person accepts any liability for any losshowsoever arising, directly or indirectly, from this presentation or its contents.
• This presentation includes forward-looking statements that reflect the Company's intentions, beliefs or current expectations concerning, among other things, theCompany’s results, condition, performance, prospects, growth, strategies and the industry in which the Company operates. These forward-looking statements aresubject to risks, uncertainties and assumptions and other factors that could cause the Company's actual results, condition, performance, prospects, growth oropportunities, as well as those of the markets it serves or intends to serve, to differ materially from those expressed in, or suggested by, these forward-lookingstatements. The Company cautions you that forward-looking statements are not guarantees of future performance and that its actual results and condition and thedevelopment of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements contained in thispresentation. In addition, even if the Company's results, condition, and growth and the development of the industry in which the Company operates are consistent withthe forward-looking statements contained in this presentation, those results or developments may not be indicative of results or developments in future periods. TheCompany and each of its directors, officers and employees expressly disclaim any obligation or undertaking to review, update or release any update of or revisions toany forward-looking statements in this presentation or any change in the Company's expectations or any change in events, conditions or circumstances on whichthese forward-looking statements are based, except as required by applicable law or regulation.
• In this presentation, references are made to the Company’s product candidates, for which marketing authorisation has not yet been obtained. These productcandidates are designated throughout this presentation by their internal project names at the Company. The names used are not meant to refer to these products (ifand when they will be approved), as it is yet uncertain if and under what names these product candidates would be marketed in the future. Nothing in this presentationshould be construed as endorsing or advertising such product candidates.
57
CONTACTS
ASIT Biotech
Thierry Legon – CEO
Tel.: +32 2 264 03 90
www.asitbiotech.com
Top Related